Beam Therapeutics price target raised to $42 from $26 at Barclays

Barclays analyst Gena Wang raised the firm’s price target on Beam Therapeutics to $42 from $26 and keeps an Equal Weight rating on the shares. The company’s Q4 was largely in line and it reiterated a cash position of $1.2B with a runway into 2027 and on-track development of clinical pipelines, the analyst tells investors in a research note.